Trial Profile
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Nivolumab (Primary)
- Indications Liver cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 28 Jul 2023 Results published in the BMC Cancer
- 04 Aug 2020 Status changed from active, no longer recruiting to completed.
- 02 Jul 2020 Planned End Date changed from 12 Jun 2020 to 7 Jul 2020.